Drug recall · September 13, 2023
Nexlizet recall
Why: Failed dissolution specifications: below specification results at stability 12-month
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc, Ann Arbor, MI 48108, NDC 72426-818-03
- Lots / codes
Lot# 1904872, Exp 1/31/2025; 1950377, Exp 6/30/2025
- Quantity
- 45,240 bottles
- Company
- Esperion, Ann Arbor, MI
- Distribution
- Nationwide USA
- Initiated
- August 16, 2023 · Voluntary: Firm initiated
- Classified
- September 6, 2023
- Reported
- September 13, 2023
- Ended
- August 31, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Nexlizet
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.